This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Opel, D. Articles by Fulda, S. Search for Related Content PubMed PubMed Citation Articles by Opel, D. Articles by Fulda, S.

Activation of Akt Predicts Poor Outcome in Neuroblastoma

¹ University Children's Hospital, Ulm, Germany; ² Institute of Pathology, Heinrich-Heine-University, Düsseldorf, Germany; and ³ Children's Hospital, Paediatric Oncology, University of Cologne, Cologne, Germany

Requests for reprints: Simone Fulda, University Children's Hospital, Eythstrasse 24, D-89075 Ulm, Germany. Phone: 49-731-5002-5980; Fax: 49-731-5002-6765; E-mail: simone.fulda{at}uniklinik-ulm.de.

Whereas aberrant activation of the phosphatidylinositol 3'-kinase (PI3K)/Akt pathway, a key survival cascade, has previously been linked to poor prognosis in several human malignancies, its prognostic effect in neuroblastoma has not yet been explored. We therefore investigated the phosphorylation status of Akt, S6 ribosomal protein as target of mammalian target of rapamycin, and extracellular signal–regulated kinase (ERK) in 116 primary neuroblastoma samples by tissue microarray and its correlation with established prognostic markers and survival outcome. Here, we provide for the first time evidence that phosphorylation of Akt at serine 473 (S473) and/or threonine 308 (T308), S6 ribosomal protein, and ERK frequently occurs in primary neuroblastoma. Importantly, we identified Akt activation as a novel prognostic indicator of decreased event-free or overall survival in neuroblastoma, whereas phosphorylation of S6 ribosomal protein or ERK had no prognostic effect. In addition, Akt activation correlated with variables of aggressive disease, including MYCN amplification, 1p36 aberrations, advanced disease stage, age at diagnosis, and unfavorable histology. Monitoring Akt at T308 or both phosphorylation sites improved the prognostic significance of Akt activation in neuroblastoma specimens compared with S473 phosphorylation. Parallel experiments in neuroblastoma cell lines revealed that activation of Akt by insulin-like growth factor (IGF)-I significantly inhibited tumor necrosis factor–related apoptosis-inducing ligand– or chemotherapy-induced apoptosis in a PI3K-dependent manner because the PI3K inhibitor LY294002 completely reversed the IGF-I–mediated protection of neuroblastoma cells from apoptosis. By showing that activation of Akt correlates with poor prognosis in primary neuroblastoma in vivo and with apoptosis resistance in vitro, our findings indicate that Akt presents a clinically relevant target in neuroblastoma that warrants further investigation. [Cancer Res 2007;67(2):735–45]

This article has been cited by other articles:

				T. Van Maerken, L. Ferdinande, J. Taildeman, I. Lambertz, N. Yigit, L. Vercruysse, A. Rihani, M. Michaelis, J. Cinatl Jr, C. A. Cuvelier, et al. Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53 J Natl Cancer Inst, November 18, 2009; 101(22): 1562 - 1574. [Abstract] [Full Text] [PDF]

				E. Kim and J. Shohet Targeted Molecular Therapy for Neuroblastoma: The ARF/MDM2/p53 Axis J Natl Cancer Inst, November 18, 2009; 101(22): 1527 - 1529. [Full Text] [PDF]

				G. Liang, G. Bansal, Z. Xie, and K. M. Druey RGS16 Inhibits Breast Cancer Cell Growth by Mitigating Phosphatidylinositol 3-Kinase Signaling J. Biol. Chem., August 7, 2009; 284(32): 21719 - 21727. [Abstract] [Full Text] [PDF]

				M. W. Ronellenfitsch, D. P. Brucker, M. C. Burger, S. Wolking, F. Tritschler, J. Rieger, W. Wick, M. Weller, and J. P. Steinbach Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death Brain, June 1, 2009; 132(6): 1509 - 1522. [Abstract] [Full Text] [PDF]

				P. Obexer, J. Hagenbuchner, T. Unterkircher, N. Sachsenmaier, C. Seifarth, G. Bock, V. Porto, K. Geiger, and M. Ausserlechner Repression of BIRC5/Survivin by FOXO3/FKHRL1 Sensitizes Human Neuroblastoma Cells to DNA Damage-induced Apoptosis Mol. Biol. Cell, April 1, 2009; 20(7): 2041 - 2048. [Abstract] [Full Text] [PDF]

				C. Hu, H. Li, J. Li, Z. Zhu, S. Yin, X. Hao, M. Yao, S. Zheng, and J. Gu Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling Carcinogenesis, December 1, 2008; 29(12): 2289 - 2297. [Abstract] [Full Text] [PDF]

				V. Sagulenko, D. Muth, E. Sagulenko, T. Paffhausen, M. Schwab, and F. Westermann Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death Carcinogenesis, October 1, 2008; 29(10): 1869 - 1877. [Abstract] [Full Text] [PDF]

				J. Qiao, J. Kang, T. A. Ishola, P. G. Rychahou, B. M. Evers, and D. H. Chung Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma PNAS, September 2, 2008; 105(35): 12891 - 12896. [Abstract] [Full Text] [PDF]

				D. Opel, M.-A. Westhoff, A. Bender, V. Braun, K.-M. Debatin, and S. Fulda Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis Cancer Res., August 1, 2008; 68(15): 6271 - 6280. [Abstract] [Full Text] [PDF]

				Z. Li, F. Tan, and C. J. Thiele Inactivation of glycogen synthase kinase-3 contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells Mol. Cancer Ther., December 1, 2007; 6(12): 3113 - 3121. [Abstract] [Full Text] [PDF]